TrialThe Journal of clinical endocrinology and metabolism2007

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Bogdan Balas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.